Rating: Hold — Conviction: Low
Ryan Specialty is a good franchise. It still grows organically at 6.7% while the largest listed wholesale competitor's specialty unit shrinks. But on filed numbers the stock is not cheap: 18.2x GAAP EBITDA, with net debt 4.5x that EBITDA. The model's base case lands on today's price, so the market is already paying for mid-single-digit growth and a margin recovery. The earlier same-day Buy rested on an aggregator EBITDA about 14% above what the 10-K reports.
Conviction tests (3a-v-c): T1 fail — Hold → Buy at −1pp (base +17.8%); −16.5% at +1pp stays Hold · T2 pass · T3 pass · T4 pass
Business overview
Ryan Specialty places hard-to-place commercial risks for retail brokers. Wholesale brokerage was about 55% of Q2 2026 revenue. It also underwrites for insurers through MGUs and programs (underwriting management, ~34%) and binds small risks under delegated authority (binding authority, ~11%). Filed revenue grew about 20% a year from FY2021 to FY2025, to $3.05bn, helped by $1.71bn of acquisitions in 2024 and $746mm in 2025. H1 2026 revenue rose 10.8%. Q2 organic growth was 6.7%, and FY2026 organic growth is guided to mid-single digits with the adjusted EBITDAC margin down 50–100bp. Earnings turn on E&S premium flow and rates (property falling, casualty firmer), producer compensation, and interest on $3.63bn of debt.
Competition
The competitors that matter are Amwins and CRC (both private) and Brown & Brown's Specialty Distribution segment. Brown & Brown's specialty unit reported organic revenue down 3.5% in Q2 2026 (10-Q, quarter to 2026-06-30), as catastrophe property rates fell 15–35%. Its segment margin fell 400bp. Ryan grew 6.7% in the same quarter, which points to share gains in casualty and underwriting management. Pressure shows up first in property commissions, then in casualty and binding authority. On stockanalysis TTM EV/EBITDA (2026-09-28), Brown & Brown trades at 9.5x, WTW at 11.6x and Gallagher at 16.7x; Ryan is 14.8x on the same page. Brown & Brown's 9.5x reflects its own organic stall, so it is a floor, not a fair comparable.
Bull case
- E&S flow proves structural. Casualty business keeps moving into the E&S channel and underwriting management keeps compounding. Organic growth stays near high single digits and today's multiple holds. Plays out if casualty rate increases persist and property declines bottom in 2027. Model: rev_growth, exit_ev_ebitda
- Margin recovers past 2025. The Empower restructuring ($33.4mm in Q2 alone) and the integration of the 2024–25 MGU acquisitions lift GAAP EBITDA margin from ~24% in 2026 toward 28%. Plays out if the adjusted margin stabilizes after 2026 and restructuring charges stop. Model: ebitda_margin
- Deleveraging. Cash flow cuts net leverage from 4.5x toward ~2.2x by FY2030 in the base path. Model: not in the value range — in this module debt paydown moves EPS and the net-cash path only; value uses FY0 net debt.
Bear case
- The soft market spreads. Cat property rates keep falling and standard carriers pull casualty back from E&S, so revenue stalls in 2027. Plays out if Ryan's organic growth falls below 3% in Q3–Q4 2026. Model: rev_growth, wacc
- Operating deleverage. Producer compensation is sticky, so flat revenue takes the GAAP margin back to ~22%, the FY2022–FY2024 level. Plays out if the FY2026 adjusted margin cut exceeds 100bp. Model: ebitda_margin
- A diversified-broker multiple. A levered wholesaler without growth trades like Brown & Brown or WTW. Model: exit_ev_ebitda
Valuation & balance sheet
| Metric (definition) | Current | Own history (range or 5y avg) | Peers | Source, as-of |
|---|---|---|---|---|
| EV/EBITDA, aggregator (TTM, adjusted-style EBITDA $909mm) | 14.8x | n/a (unverified) | BRO 9.5x · WTW 11.6x · AJG 16.7x | stockanalysis.com, 2026-09-28 |
| EV/EBITDA, model basis (EV $14.19bn incl. $464mm TRA; filed GAAP EBITDA; leases excluded) | 18.2x FY2025 · 18.6x TTM | n/a | n/a (peers not restated) | model-inputs.json, 10-K, Q2 release |
| Forward P/E (stockanalysis consensus, adjusted EPS) | 16.6x | n/a (unverified) | BRO 13.1x · WTW 14.0x · AJG 16.5x | stockanalysis.com, 2026-09-28 |
| FCF yield (OCF − capex, FY2025) | 5.6% ($576mm); 4.8% after tax distributions and TRA payments | $264mm–$576mm FY2021–FY2025 | n/a | FY2025 and FY2023 10-K cash flows |
Model-implied value range (from model-summary.json; generic module, Gordon-growth DCF and exit-EV/EBITDA DCF, midpoints): Bear $16.53 · Base $37.27 · Bull $60.27 per share, i.e. implied returns of −56.6% / −2.2% / +58.1% vs $38.12. These ranges show how the bull and bear drivers translate into value; they are not price targets. The price sits on the base case, halfway between bear and bull, so the market prices neither the spreading soft market nor a return to high-single-digit organic growth. The base exit of 15x is a 17.5% de-rating from 18.2x FY2025 (19% from 18.6x TTM). The two methods agree within 4% (Gordon $37.96, exit $36.58), so neither embeds a re-rating.
Tail. Wholesale brokerage is ~55% of revenue, so a harsher bear was run on a scratch copy: revenue +5% / −4% / −2% / +2% / +3%, GAAP EBITDA margin 22.5% falling to 19–20%, NWC −3% of revenue, a 10x exit and a 10% WACC. It gives $6.23 (−83.7%). Leverage makes the tail steep.
Balance sheet: net leverage 4.5x FY2025 GAAP EBITDA (model Credit), coverage 3.6x. Liquidity: $140mm cash (excluding fiduciary funds) plus $1,043mm undrawn on the $1.4bn revolver. Debt at principal is $3,632mm: the term loan B ($1,675mm), revolver draw ($357mm), 4.375% secured notes due February 2030 ($400mm) and 5.875% secured notes due 2032 ($1.2bn). The nearest material maturity is the 2030 notes; the revolver and term loan maturities weren't retrieved (2029 and 2031 assumed). TRA liabilities are $464mm. Ratings: n/a (unverified).
Model note:
- Tier
full, statusbuilt, verificationverified(LibreOffice matched all 3,207 formula cells). Scenario consistencyOKon all 14 rows. No assumptions without basis. - Unverified input: diluted shares (268.5mm, derived from Q2 adjusted net income ÷ adjusted diluted EPS). The filed Class A + B count is 255.8mm. Using it lifts base value 5% to $39.12.
- Historicals are from EDGAR and the 10-Ks. Filed FY2025 EBITDA is $781.2mm, not the $887.2mm aggregator figure the earlier model used. Term loan and revolver balances come from the 10-Q via a search summary.
- GAAP EBITDA is after equity compensation, contingent-consideration remeasurement and Empower restructuring; adjusted EBITDAC adds these back. Contingent consideration liabilities were not retrieved and are not in
other_claims. - Base WACC (8.1%) carries a stated ~100bp premium over the 7.12% CAPM-based figure, for 4.5x leverage.
- Base Y1 GAAP EPS of $0.84 is far below the ~$2.30 adjusted EPS implied by the 16.6x forward P/E. There is no company EPS guidance. The adjusted figure adds back amortization, equity compensation, restructuring and earn-out remeasurement; the model EPS is not meant to match it.
Scenario stress test
Reasoned from the bull/bear drivers above. The model column comes from the scenario overlays (Base case + shock).
| Scenario | Effect | Mechanism | Magnitude | Model Δ value vs Base ($/sh) |
|---|---|---|---|---|
| S1 Fast equity crash | − | Market de-rating of a levered roll-up; no operating channel | Med | −$3.31 |
| S2 Slow bear / recession | − | Exposure units (payroll, construction, transport) shrink while rates hold. About 30% of Base − Bear ($20.74), because a recession is a transitory exposure hit and the bear case is a permanent soft market | High | −$6.24 |
| S3 Rapid rate shock | − | Higher discount rate; floating term loan and revolver cost more; fiduciary income rises slightly (not modeled) | High | −$6.48 |
| S4 Slow rate grind | − | Same channel, grinding | Med | −$4.09 |
| S5 Soft-landing cuts | + | Lower rates on a levered balance sheet; exposure growth intact | High | +$8.25 |
| S6 Recession-driven cuts | − | Exposures shrink and fiduciary income falls, only partly offset by lower rates | Low | −$0.39 |
| S7a Credit liquidity shock | − | Leveraged-loan spreads gap wider on a ~4.5x-levered secured structure; forced selling | Med | −$3.31 |
| S7b Slow default cycle | − | Refinancing cost rises; insured small-business exposures shrink | Med | −$3.40 |
| S8 Stagflation | + | Loss-cost inflation pushes premium rates and commissions up; a higher discount rate partly offsets | Low | +$2.01 |
| S9a Dollar spike | − | Small UK and European operations translate lower | Low | −$0.24 |
| S9b Dollar slide | + | Mirror of S9a | Low | +$0.24 |
| S10 Melt-up | + | Beaten-down growth financials re-rate | Low | +$2.49 |
| S11 Energy supply shock | ± | Energy and marine premium rates rise; costs offset | Low | +$0.22 |
| S12 Mega-cap/AI derating | 0 | No material effect, not modeled; not AI-linked | — | $0.00 |
Currently active/on watch per the playbook: state.md lists S3 as partially active; the macro log records all three legs crossed from 2026-09-24 (10Y 5.17% on 2026-09-25). S8, S10 and S11 are on watch. S3 is High here; S8, S10 and S11 are Low.
What would change the call
Upgrades if:
- Q3 2026 organic growth holds ≥5% against the year's toughest comparison, with the adjusted margin cut at or under 50bp and restructuring charges tapering; or
- Net leverage falls below 3.5x on GAAP EBITDA without a slowdown in growth.
Downgrades if:
- Organic growth falls below 3% in Q3 or Q4 2026, or the property book decline accelerates; or
- Leverage rises again through debt-funded M&A or buybacks while growth slows.
Watch items
- W1: Q3 2026 organic growth (Q2 +6.7%; FY guide mid-single digits). Source: Q3 2026 release (late October 2026, date n/a unverified). Model: rev_growth
- W2: Adjusted EBITDAC margin against the "down 50–100bp" guide, and Empower restructuring charges (Q2 $33.4mm). Source: Q3 2026 release. Model: ebitda_margin
- W3: Brown & Brown Specialty Distribution organic growth, as a read on wholesale property (Q2 −3.5%). Source: BRO Q3 2026 release. Model: rev_growth
- W4: Net leverage and the capital-allocation mix (Q2 buybacks $260mm; revolver draw $357mm). Source: Q3 2026 10-Q. Model: none
Sources
- SEC EDGAR XBRL companyconcept, Revenues and OperatingIncomeLoss (CIK 1849253) — https://data.sec.gov/api/xbrl/companyconcept/CIK0001849253/us-gaap/Revenues.json · https://data.sec.gov/api/xbrl/companyconcept/CIK0001849253/us-gaap/OperatingIncomeLoss.json — accessed 2026-09-28
- Ryan Specialty FY2025 Form 10-K (income statement R3, balance sheet R5, cash flows R7), filed 2026-02-13 — https://www.sec.gov/Archives/edgar/data/1849253/000184925326000006/R3.htm — accessed 2026-09-28
- Ryan Specialty FY2023 Form 10-K (balance sheet R4, cash flows R6) — https://www.sec.gov/Archives/edgar/data/1849253/000095017024021657/R6.htm — accessed 2026-09-28
- Ryan Specialty Q2 2026 results (8-K ex. 99.1, 2026-07-30) — https://www.sec.gov/Archives/edgar/data/0001849253/000184925326000034/ryan-20260630xex991.htm — accessed 2026-09-28
- Ryan Specialty Form 10-Q, quarter ended 2026-06-30 (cover share count; debt note via search summary) — https://www.sec.gov/Archives/edgar/data/0001849253/000184925326000036/ryan-20260630.htm — accessed 2026-09-28
- EDGAR filing list and 8-K 2026-08-07 (option settlement amendment, share-count neutral) — https://data.sec.gov/submissions/CIK0001849253.json · https://www.sec.gov/Archives/edgar/data/0001849253/000184925326000040/ryan-20260804.htm — accessed 2026-09-28
- Ryan Specialty statistics (price, beta, aggregator multiples) — https://stockanalysis.com/stocks/ryan/statistics/ — accessed 2026-09-28
- Peer statistics: BRO https://stockanalysis.com/stocks/bro/statistics/ · AJG https://stockanalysis.com/stocks/ajg/statistics/ · WTW https://stockanalysis.com/stocks/wtw/statistics/ — accessed 2026-09-28
- Brown & Brown Q2 2026 10-Q (Specialty Distribution organic revenue) — https://www.sec.gov/Archives/edgar/data/0000079282/000119312526318251/bro-20260630.htm — accessed 2026-09-28 (via search summary)
- Daily macro log (10Y, S3 status),
logs/macro-2026-09.md, 2026-09-24/25 entries